

業績目録（令和4年）

大学院科目名：血液内科学（血液・腫瘍内科学）

(B-b) 和文総説

- 1 黒田純也. アポトーシス抵抗性 BCL2 ファミリー阻害剤 BH3-mimetic drugs の基礎と臨床. 医学の歩み 263: 518-523, 2022.
- 2 水谷信介、黒田純也. 骨髄腫の初発症状から診断まで. 内科 130: 695-699, 2022.
- 3 志村勇司. 多発性骨髄腫に対する抗体医薬の現状と展望. 血液内科 85:29-34, 2022.
- 4 塚本拓. マントル細胞リンパ腫のリスク層別化と治療戦略. 血液内科 84(3):315-321, 2022
- 5 藤野貴大. 未治療 DLBCL に対する polatuzumab vedotin 併用レジメンの開発. 血液内科 85(4):546-552, 2022

(C-a) 英文原著

- 1 Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T, Goto H, Jackson C, Sun H, Pacaud L, Fujikawa E, Yeh T, Hatayama T, Aida K, Sunagawa Y, Iida S. Ciltacabtagene. in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. Cancer Sci 113: 4267-4276, 2022. (IF=6.518)
- 2 Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Otsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H. Final analysis of randomized phase 2 study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer Sci 113: 3267-3270, 2022. (IF=6.518)
- 3 Maekura C, Muramatsu A, Nagata H, Okamoto H, Onishi A, Kato D, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, Okumura K, Inaba T, Nukui Y, Kuroda J. Clinical implication of the effect of the production of neutralizing antibodies

- against SARS-Cov-2 for chronic immune thrombocytopenia flare-up associated with COVID-19 infection; a case report and the review of literature. *Infect Drug Resist* 15: 2723-2728, 2022. (IF=4.177)
- 4 Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida S, Nakaya A, Ito T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J, Kansai Myeloma Forum. Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: A multicenter retrospective analysis. *Ther Adv Hematol* 13: 20406207221104584, 2022. (IF=5.4)
 - 5 Katagiri S, Chi SG, Minami Y, Fukushima K, Shibayama H, Hosono N, Yamauchi T, Morishita T, Kondo T, Yanada M, Yamamoto K, Kuroda J, Usuki K, Akahane D, Gotoh A. Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia. *Int J Mol Sci* 23: 4694, 2022. (IF=6.208)
 - 6 Murakami S, Ri M, Ito M, Nakamura N, Kasahara S, Kitagawa J, Inagaki Y, Kuroda J, Yoshimitsu M, Okamoto A, Fukuhara N, Taji H, Iida H, Nagai H, Hanamura I, Tsujimura H, Okura M, Kurata M, Kuwatsuka Y, Atusta Y, Iida S. Efficacy and safety of modified BLD therapy for transplant-ineligible Japanese patients with multiple myeloma. *Int J Hematol* 116: 563-659, 2022. (IF=2.324)
 - 7 Matsue K, Sunami K, Matsumoto M, Kuroda J, Sugiura I, Iwasaki H, Chung W, Kuwayama S, Nishio M, Lee K, Iida S. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. *Int J Hematol* 116: 122-130, 2022. (IF=2.324)
 - 8 Inaba T, Okumura K, Maekura C, Muramatsu A, Kobayashi T, Kuroda J, Nukui Y. Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination. *Int J Hematol* 115: 916-917, 2022. (IF=2.324)
 - 9 Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y,

- Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H. NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia. *Int J Hematol* 116: 199–214, 2022. (IF=2.324)
- 10 Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. The rationale for the dual targeting therapy for RSK2 and AKT in multiple myeloma. *Int J Mol Sci* 23: 2919, 2022. (IF=6.208)
- 11 Kobayashi T, Yamamoto K, Kagami Y, Machida R, Miyazaki K, Nakamura S, Kuroda J, Maruyama D, Nagai H. Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial. *Jpn J Clin Oncol* 52: 583–588, 2022. (IF=2.925)
- 12 Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, Rai S, Kuroda J, Ishizawa K, Ichikawa S, Ando K, Ogura M, Fukushima K, Terui Y. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. *Ann Hematol* 101: 979–989, 2022. (IF=4.03)
- 13 Tomida A, Chiyonobu T, Tokuda S, Miyachi M, Murashima K, Hirata M, Nakagawa M, Iehara T, Kuroda J, Takayama K. Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant. *Hum Genome Var* 8: 8, 2022. (IF=0.586)
- 14 Fujino T, Maruyama D, Miyagi-Maeshima A, Tajima K, Saito Y, Ida H, Hosoba R, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Kuroda J, Izutsu K. The outcome of watchful waiting in patients with previously treated follicular lymphoma. *Cancer Med* 11:

- 2106-2116, 2022. (IF=4.711)
- 15 Kitaoji T, Noto Y, Kasai T, Mizuhara K, Okamoto H, Tsukamoto T, Kuroda J, Mizuno T. A case of neuroleukemiosis: The usefulness of nerve ultrasound as a diagnostic tool. *Muscle Nerve* 65: E19-E21, 2022. (IF=3.852)
- 16 Kaneko H, Shimura K, Yoshida M, Matsumoto Y, Kobayashi T, Uchiyama H, Kuroda J, Taniwaki M. Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Combined Chemotherapy. *Int J Hematol-Oncol Stem Cell Research* 16: 1-8, 2022. (IF=0.239)
- 17 Muramatsu A, Kobayashi T, Kawaji-Kanayama Y, Uchiyama H, Sasaki N, Uoshima N, Nakao M, Takahashi R, Shimura K, Kaneko H, Kiyota M, Wada K, Chinen Y, Hirakawa K, Fuchida S, Shimazaki C, Mizutani S, Tsukamoto T, Shimura Y, Taniwaki M, Teramukai S, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma. *Leuk Lymphoma* 11: 1-8, 2022. (IF=2.996)
- 18 Tsukamoto T, Tokuda Y, Nakano M, Tashiro K, Kuroda J. Expression of activated B cell gene signature is predictive of the outcome of follicular lymphoma. *Blood Adv* 6: 1932-1936, 2022. (IF=7.642)
- 19 Matsumoto Y, Ayani N, Omichi C, Oya N, Matsuoka T, Kobayashi T, Kuroda J, Narumoto J. Diagnostic error about the cause of cytopenia during increasing psychotropic drugs: two case reports. *Asian J Psychiatr* 67: 102952, 2022. (IF=13.89)
- 20 Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J, Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study. *Int J Hematol* 115, 350-362, 2022. (IF=2.324)

- 21 Hatta S, Fukuhara S, Fujino T, Saito Y, Ito Y, Makita S, Munakata W, Suzuki T, Maruyama D, Kusumoto M, Izutsu K. The role of surveillance computed tomography in patients with follicular lymphoma. *Ther Adv Hematol.* ;13:20406207221095963, 2022. (IF=5.4)
- 22 Shimomura Y, Sobue T, Hirabayashi S, Kondo T, Mizuno S, Kanda J, Fujino T, Kataoka K, Uchida N, Eto T, Miyakoshi S, Tanaka M, Kawakita T, Yokoyama H, Doki N, Harada K, Wake A, Ota S, Takada S, Takahashi S, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanada M. Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. *Leukemia* 36:1132-1138, 2022. (IF=12.897)
- 23 Onishi C, Nishikori M, Yakushijin K, Kurahashi S, Nakazawa H, Takamatsu Y, Hashimoto Y, Tatetsu H, Yuichiro Nawa, Yoshida M, Kobayashi T, Oyake T, Yano S, Oride A, Suzuki R. Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study. *Int J Hematol* 115: 382-390, 2022. (IF=2.324)
- 24 Taminishi-Katsuragawa Y, Shimura Y, Inoue Y, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Kobayashi T, Takeda-Miyata N, Nishimura A, Takatsuka K, Kuroda J. Gastric myeloid sarcoma mimicking a scirrhous gastric cancer. *Intern Med* 61:1231-1235, 2022. (IF=1.282)

(D) 学会発表等

II) シンポジウム、ワークショップ、パネルディスカッション等

- 1 黒田純也. シンポジウム4『臨床研究・治験における製薬企業への要望と課題』臨床系医学教室における臨床研究の意義と課題 ～ある血液内科学教室の場合～. 第13回日本製薬医学会年次大会, 2022, 東京.
- 2 塚本 拓、木下将希、今久保桃子、山田和宏、山口敏和、水谷信介、志村勇司、古林 勉、稲澤譲治、黒田純也. シンポジウム イメージングフローサイトメトリーを用いた骨髄腫関連 IGH 転座のマルチプレックス FISH 診断法の開発. 第47回日本骨髄腫学会, 2022, 岐阜
- 3 黒田純也. 臓器別ワークショップ33 多発性骨髄腫の病態形成を司る疾患特異的・普遍的異常の探索. 第60回日本癌治療学会学術集会, 2022, 兵庫.

- 4 塚本拓. シンポジウム 6. ” Towards the best management of MM” 多発性骨髄腫における細胞遺伝学異常の温故知新. 第 84 回日本血液学会学術集会. 2022, 福岡.

III) 国際学会における一般発表

- 1 Marumo A, Wakita S, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Akiko H, Muto H, Sato E, Ogata M, Mitsunashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Fukuda T, Kanda Y, Yamaguchi H. Mutational Analysis of *DNMT3A* Improves the Prognostic Stratification Using *NPM1/FLT3*-ITD Genotypes in Patients with Acute Myeloid Leukemia. The American Society of Hematology 64th Annual Meeting and Exposition. 2022 Dec 10-13; USA.
- 2 Watanabe T, Tobinai K, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, Ogura M, Kuroda J, Suehiro Y, Matsuno Y, Tsukasaki K, Nagai H. Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma. The American Society of Hematology 64th Annual Meeting and Exposition. 2022 Dec 10-13; USA.
- 3 Mizuhara K, Shimura Y, Tsukamoto T, Kanai A, Kuwahara-Ota S, Yamaguchi J, Muramatsu A, Okamoto H, Katsuragawa-Taminishi Y, Kawaji-Kanayama Y, Isa R, Mizutani S, Inaba T, Kuroda J. Mir-106a-5p and Mir-146a-5p Delivered By Tumor-Derived Exosomes Promote the Induction of Myeloid-Derived Suppressor Cells from Normal Peripheral Blood Mononuclear Cells in Multiple Myeloma. The American Society of Hematology 64th Annual Meeting and Exposition 2022 Dec 10-13; USA.
- 4 Iino M, Horigome Y, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Yoshida T, Mori I, Abe M, Akagi K, Hayashi T, Ishida T, Ito S, Iwasaki H, Kuroda J, Maeda T, Shibayama H, Sunami K, Takamatsu H, Tamura H, Shinozaki T,

- Iida S. A Prospective, Multicenter, Observational Study of Ixazomib plus Lenalidomide-Dexamethasone in 295 Japanese Patients with Relapsed/Refractory Multiple Myeloma. 19th International Myeloma Society Annual Meeting. 2022 Aug 25-27; Los Angeles, USA.
- 5 Fonseca R, Kuroda J, Ishida T, Papot R, Huang JSY, Yver A, Vandendries E, Elmeliegy M, Ma WD, Sborov DW. MagnetisMM-9: An Open-Label, Multicenter, Non-Randomized Phase 1/2 Study of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma. The 2022 ASCO Annual Meeting, 2022 Jun 3-7; Chicago, USA.
- 6 Fonseca R, Kuroda J, Ishida T, Popat R, Huang JS, Yver A, Vandendries E, Elmeliegy M, Ma WD, Sborov DW. MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. The 27th Congress, European Hematology Association VIRTUAL. 2022, Jun.
- 7 Tsukamoto T, Kinoshita M, Yamada K, Yamaguchi T, Chinen Y, Mizutani S, Fujino T, Shimura Y, Kobayashi T, Inazawa J, Kuroda J. IMMUNOPHENOTYPED-SUSPENSION-MULTIPLEX FISH BY IMAGING FLOW CYTOMETRY FOR THE SIMULTANEOUS DIAGNOSIS OF THREE PIVOTAL IGH TRANSLOCATIONS IN MULTIPLE MYELOMA. The 27th Congress, European Hematology Association VIRTUAL. 2022, Jun.
- 8 Mizuhara K, Kobayashi T, Nakao M, Takahashi R, Kaneko H, Shimura K, Hirakawa K, Uoshima N, Kamitsuji Y, Wada K, Kawata E, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Mizutani S, Shimura Y, Taniwaki M, Kuroda J. WATCHFUL WAITING IS AN ACCEPTABLE TREATMENT OPTION FOR PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: A RETROSPECTIVE STUDY. The 27th Congress, European Hematology Association VIRTUAL. 2022, Jun.

E 研究助成（競争的研究助成金）

公的助成

代表（総額）・小計 560 万円

1. 黒田純也 文部科学省科学研究費補助金基盤研究 (C) 令和 4～6 年度
全ての成熟リンパ系腫瘍の制御に向けた RSK2/AKT/S6K 同時標的治療薬
の開発 助成金額 130 万円
2. 志村勇司 文部科学省科学研究費補助金基盤研究 (C) 令和 4～6 年度
造血器腫瘍における MDSC を標的とした miRNA インヒビターカクテル療
法の開発 助成金額 90 万円
3. 水谷信介 文部科学省科学研究費補助金若手研究 令和 3～4 年
普遍的成熟 B 細胞腫瘍モデル細胞の網羅的遺伝子編集による高悪性度病
態形成機序の解明 助成金額 180 万円
4. 塚本 拓 文部科学省科学研究費補助金若手研究 令和 3～5 年度
Galectin-9 を介したマントル細胞リンパ腫の BCR シグナル活性化機序
の解明 助成金額 160 万円

分担・小計 1,434,300 円

1. 黒田純也 AMED 革新的がん医療実用化研究事業 令和 3～6 年度
高齢者多発性骨髄腫に対する標準治療の確立と治療効果・耐性獲得に関
わる分子基盤の探索 助成金額 30 万円
2. 黒田純也 AMED 臨床研究・治験推進研究事業 令和 2～5 年度
急性骨髄性白血病に対する治療用がんペプチドワクチン「DSP-7888」の
Phase2 医師主導治験 助成金額 1,134,300 円

財団等からの助成

代表（総額）・小計 280 万円

1. 黒田純也. 先進医薬研究振興財団第 41 回一般研究助成 2「血液医学分野
助成」. 令和 4 年度
造血器腫瘍に対する細胞免疫療法を強化する miRNA インヒビターカクテ
ル療法の開発 100 万円
2. 黒田純也. 日本血液学会 2022 年度研究助成. 令和 4 年度 5H-pyrrolo[2,3-
d]pyrimidin-6(7H)-one 誘導体の最適化による全ての成熟リンパ系腫瘍
の制御を目指す RSK2/AKT/S6K 同時標的治療薬の開発 100 万円
3. 志村勇司. 日本血液学会 2022 年度研究助成. 令和 4 年度
多発性骨髄腫における腫瘍由来エクソソームの解析および新規治療戦略
開発 30 万円
4. 塚本拓. 公益財団法人公益推進協会 ENT M Dr. 浅野登&暉子基金 医学基

礎研究助成事業. マントル細胞リンパ腫における B 細胞受容体シグナル
ソーム形成異常を介した疾患形成機構の解明 50 万円